Bioactivation and reactivity research advances–2023 year in review

Advances in the field of bioactivation have significantly contributed to our understanding and prediction of drug-induced liver injury (DILI). It has been established that many adverse drug reactions, including DILI, are associated with the formation and reactivity of metabolites. Modern methods allow us to detect and characterize these reactive metabolites in earlier stages of drug development, which helps anticipate and circumvent the potential for DILI. Improved <i>in silico</i> models and experimental techniques that better reflect in vivo environments are enhancing predictive capabilities for DILI risk. Further, studies on the mechanisms of bioactivation, including enzyme interactions and the role of individual genetic differences, have provided valuable insights for drug optimizations. Cumulatively, this progress is continually refining our approaches to drug safety evaluation and personalized medicine. Shuai Wang and Cyrus Khojasteh, on behalf of the authors.生物激活（bioactivation）领域的研究进展，极大提升了我们对药物性肝损伤（drug-induced liver injury, DILI）的认知与预测水平。已有研究证实，包括药物性肝损伤在内的诸多药物不良反应，均与代谢物的生成及其反应活性密切相关。现代检测技术可在药物研发早期阶段对这类反应性代谢物进行检测与表征，从而助力预判并规避药物性肝损伤的潜在风险。经过优化的计算机模拟（in silico）模型与更贴合体内（in vivo）环境的实验技术，正不断提升药物性肝损伤风险的预测能力。此外，针对生物激活机制的研究——包括酶相互作用与个体遗传差异的作用——也为药物优化提供了宝贵的研究思路。综合而言，上述研究进展正持续完善我们在药物安全性评价与个性化医疗领域的研究路径。王帅与赛勒斯·霍贾斯特（Cyrus Khojasteh） 谨代表全体作者。